Literature DB >> 16075416

Serum 1H-nuclear magnetic spectroscopy followed by principal component analysis and hierarchical cluster analysis to demonstrate effects of statins on hyperlipidemic patients.

Laurence Le Moyec1, Paul Valensi, Jean-Christophe Charniot, Edith Hantz, Jean-Paul Albertini.   

Abstract

Use of statins for prevention of coronary heart disease is based on the decrease of serum cholesterol and LDL cholesterol. To better investigate the changes in lipid profile after statin treatment, we propose here to use an analysis of serum by proton nuclear magnetic resonance (NMR) spectroscopy associated with a multivariate analysis of the main spectral components. Sera were obtained from 60 male patients treated for 6 weeks with simvastatin (30 patients) or atorvastatin (30 patients) for who LDL cholesterol decreased by over 45% in all selected patients. Proton nuclear magnetic resonance spectra were obtained and the region of methyl resonance from lipids was separated into six consecutive lines attributed to lipids which were analyzed by principal component analysis (PCA) and clustering by hierarchical cluster analysis (HCA) based on Euclidian distance coupled with the Ward's minimum variance method. PCA and HCA gave a map discriminating the 120 samples into five clusters, three clusters containing samples obtained at baseline and two others containing samples obtained after treatment. Both statins produced a decrease in lower-density lipoprotein components and an increase in higher density lipoprotein components. Patients with a coronary heart disease history could be discriminated after treatment by the increase in the component containing the highest proportion of HDL. Proton NMR spectroscopy of sera coupled with a PCA and an HCA was able to detect variations in the metabolism of lipids resulting from statin treatments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16075416     DOI: 10.1002/nbm.974

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  6 in total

1.  Influence of common preanalytical variations on the metabolic profile of serum samples in biobanks.

Authors:  Ophélie Fliniaux; Gwenaelle Gaillard; Antoine Lion; Dominique Cailleu; François Mesnard; Fotini Betsou
Journal:  J Biomol NMR       Date:  2011-10-02       Impact factor: 2.835

2.  NMR-based prediction of cardiovascular risk in diabetes.

Authors:  Ronan Roussel; France Mentré; Nadia Bouchemal; Samy Hadjadj; Michel Lièvre; Gilles Chatellier; Joël Menard; Xavière Panhard; Anne Le Hénanff; Michel Marre; Laurence Le Moyec
Journal:  Nat Med       Date:  2007-04       Impact factor: 53.440

3.  Rearrangement of energetic and substrate utilization networks compensate for chronic myocardial creatine kinase deficiency.

Authors:  Petras P Dzeja; Kirsten Hoyer; Rong Tian; Song Zhang; Emirhan Nemutlu; Matthias Spindler; Joanne S Ingwall
Journal:  J Physiol       Date:  2011-08-30       Impact factor: 5.182

4.  Metabolomics in Exercise and Sports: A Systematic Review.

Authors:  Kayvan Khoramipour; Øyvind Sandbakk; Ammar Hassanzadeh Keshteli; Abbas Ali Gaeini; David S Wishart; Karim Chamari
Journal:  Sports Med       Date:  2021-10-30       Impact factor: 11.136

Review 5.  Metabolomics-based methods for early disease diagnostics.

Authors:  G A Nagana Gowda; Shucha Zhang; Haiwei Gu; Vincent Asiago; Narasimhamurthy Shanaiah; Daniel Raftery
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

6.  Human metabolic profiles are stably controlled by genetic and environmental variation.

Authors:  George Nicholson; Mattias Rantalainen; Anthony D Maher; Jia V Li; Daniel Malmodin; Kourosh R Ahmadi; Johan H Faber; Ingileif B Hallgrímsdóttir; Amy Barrett; Henrik Toft; Maria Krestyaninova; Juris Viksna; Sudeshna Guha Neogi; Marc-Emmanuel Dumas; Ugis Sarkans; Bernard W Silverman; Peter Donnelly; Jeremy K Nicholson; Maxine Allen; Krina T Zondervan; John C Lindon; Tim D Spector; Mark I McCarthy; Elaine Holmes; Dorrit Baunsgaard; Chris C Holmes
Journal:  Mol Syst Biol       Date:  2011-08-30       Impact factor: 11.429

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.